24 July 2024 | Wednesday | Company results
Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2024.
Second Quarter 2024 Highlights
“Our excellent execution enabled us to deliver another quarter of strong financial performance and share gain,” said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. “We continue to see the benefit of our proven growth strategy and the impact of our PPI Business System in our performance. Shortly after the quarter ended, we were also pleased to welcome our Olink colleagues to Thermo Fisher and are excited about the power of this new combination to better serve our customers and advance science.”
Casper added, “We have made very good progress through the halfway point of the year and are in a great position to deliver differentiated performance in 2024. We’ve further extended our industry leadership and positioned our company for an even brighter future.”
Second Quarter 2024
Revenue for the quarter declined 1% to $10.54 billion in 2024, versus $10.69 billion in 2023. Organic revenue was 1% lower and Core organic revenue growth was flat.
GAAP Earnings Results
GAAP diluted EPS in the second quarter of 2024 increased 15% to $4.04, versus $3.51 in the same quarter last year. GAAP operating income for the second quarter of 2024 grew to $1.82 billion, compared with $1.58 billion in the year-ago quarter. GAAP operating margin increased to 17.3%, compared with 14.8% in the second quarter of 2023.
Non-GAAP Earnings Results
Adjusted EPS in the second quarter of 2024 increased 4% to $5.37, versus $5.15 in the second quarter of 2023. Adjusted operating income for the second quarter of 2024 was $2.35 billion, compared with $2.37 billion in the year-ago quarter. Adjusted operating margin increased to 22.3%, compared with 22.2% in the second quarter of 2023.
Annual Guidance for 2024
Thermo Fisher is raising its full-year revenue and adjusted EPS guidance. The company is raising its revenue guidance to a new range of $42.4 to $43.3 billion versus its previous guidance of $42.3 to $43.3 billion. The company is raising its adjusted EPS guidance to a new range of $21.29 to $22.07 versus its previous guidance of $21.14 to $22.02.
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.”
|
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
|
||||||
|
|
|
Three months ended |
||||||||||||
|
|
|
June 29, |
|
% of |
|
July 1, |
|
% of |
||||||
|
(Dollars in millions except per share amounts) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
|
Revenues |
|
$ |
10,541 |
|
|
|
|
$ |
10,687 |
|
|
|
||
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
|
Cost of revenues (a) |
|
|
6,106 |
|
|
57.9 |
% |
|
|
6,323 |
|
|
59.2 |
% |
|
Selling, general and administrative expenses (b) |
|
|
1,687 |
|
|
16.0 |
% |
|
|
1,673 |
|
|
15.7 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
513 |
|
|
4.9 |
% |
|
|
585 |
|
|
5.4 |
% |
|
Research and development expenses |
|
|
339 |
|
|
3.2 |
% |
|
|
345 |
|
|
3.2 |
% |
|
Restructuring and other costs (c) |
|
|
77 |
|
|
0.7 |
% |
|
|
183 |
|
|
1.7 |
% |
|
Total costs and operating expenses |
|
|
8,722 |
|
|
82.7 |
% |
|
|
9,109 |
|
|
85.2 |
% |
|
Operating income |
|
|
1,820 |
|
|
17.3 |
% |
|
|
1,578 |
|
|
14.8 |
% |
|
Interest income |
|
|
295 |
|
|
|
|
|
178 |
|
|
|
||
|
Interest expense |
|
|
(354 |
) |
|
|
|
|
(326 |
) |
|
|
||
|
Other income/(expense) (d) |
|
|
5 |
|
|
|
|
|
— |
|
|
|
||
|
Income before income taxes |
|
|
1,765 |
|
|
|
|
|
1,430 |
|
|
|
||
|
Provision for income taxes (e) |
|
|
(128 |
) |
|
|
|
|
(52 |
) |
|
|
||
|
Equity in earnings/(losses) of unconsolidated entities |
|
|
(84 |
) |
|
|
|
|
(16 |
) |
|
|
||
|
Net income |
|
|
1,553 |
|
|
|
|
|
1,362 |
|
|
|
||
|
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
6 |
|
|
|
|
|
1 |
|
|
|
||
|
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
1,548 |
|
|
14.7 |
% |
|
$ |
1,361 |
|
|
12.7 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
|
Basic |
|
$ |
4.05 |
|
|
|
|
$ |
3.53 |
|
|
|
||
|
Diluted |
|
$ |
4.04 |
|
|
|
|
$ |
3.51 |
|
|
|
||
|
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
|
Basic |
|
|
382 |
|
|
|
|
|
386 |
|
|
|
||
|
Diluted |
|
|
383 |
|
|
|
|
|
388 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
|
GAAP operating income |
|
$ |
1,820 |
|
|
17.3 |
% |
|
$ |
1,578 |
|
|
14.8 |
% |
|
Cost of revenues adjustments (a) |
|
|
1 |
|
|
0.0 |
% |
|
|
18 |
|
|
0.2 |
% |
|
Selling, general and administrative expenses adjustments (b) |
|
|
(64 |
) |
|
-0.6 |
% |
|
|
6 |
|
|
0.1 |
% |
|
Restructuring and other costs (c) |
|
|
77 |
|
|
0.7 |
% |
|
|
183 |
|
|
1.7 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
513 |
|
|
4.9 |
% |
|
|
585 |
|
|
5.4 |
% |
|
Adjusted operating income (non-GAAP measure) |
|
$ |
2,347 |
|
|
22.3 |
% |
|
$ |
2,370 |
|
|
22.2 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
|
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
1,548 |
|
|
|
|
$ |
1,361 |
|
|
|
||
|
Cost of revenues adjustments (a) |
|
|
1 |
|
|
|
|
|
18 |
|
|
|
||
|
Selling, general and administrative expenses adjustments (b) |
|
|
(64 |
) |
|
|
|
|
6 |
|
|
|
||
|
Restructuring and other costs (c) |
|
|
77 |
|
|
|
|
|
183 |
|
|
|
||
|
Amortization of acquisition-related intangible assets |
|
|
513 |
|
|
|
|
|
585 |
|
|
|
||
|
Other income/expense adjustments (d) |
|
|
— |
|
|
|
|
|
(1 |
) |
|
|
||
|
Provision for income taxes adjustments (e) |
|
|
(102 |
) |
|
|
|
|
(171 |
) |
|
|
||
|
Equity in earnings/losses of unconsolidated entities |
|
|
84 |
|
|
|
|
|
16 |
|
|
|
||
|
Noncontrolling interests adjustments (f) |
|
|
(1 |
) |
|
|
|
|
— |
|
|
|
||
|
Adjusted net income (non-GAAP measure) |
|
$ |
2,057 |
|
|
|
|
$ |
1,997 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
|
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
4.04 |
|
|
|
|
$ |
3.51 |
|
|
|
||
|
Cost of revenues adjustments (a) |
|
|
0.00 |
|
|
|
|
|
0.05 |
|
|
|
||
|
Selling, general and administrative expenses adjustments (b) |
|
|
(0.17 |
) |
|
|
|
|
0.01 |
|
|
|
||
|
Restructuring and other costs (c) |
|
|
0.20 |
|
|
|
|
|
0.47 |
|
|
|
||
|
Amortization of acquisition-related intangible assets |
|
|
1.34 |
|
|
|
|
|
1.51 |
|
|
|
||
|
Other income/expense adjustments (d) |
|
|
0.00 |
|
|
|
|
|
0.00 |
|
|
|
||
|
Provision for income taxes adjustments (e) |
|
|
(0.26 |
) |
|
|
|
|
(0.44 |
) |
|
|
||
|
Equity in earnings/losses of unconsolidated entities |
|
|
0.22 |
|
|
|
|
|
0.04 |
|
|
|
||
|
Noncontrolling interests adjustments (f) |
|
|
0.00 |
|
|
|
|
|
0.00 |
|
|
|
||
|
Adjusted EPS (non-GAAP measure) |
|
$ |
5.37 |
|
|
|
|
$ |
5.15 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
|
GAAP net cash provided by operating activities |
|
$ |
1,960 |
|
|
|
|
$ |
1,540 |
|
|
|
||
|
Purchases of property, plant and equipment |
|
|
(301 |
) |
|
|
|
|
(284 |
) |
|
|
||
|
Proceeds from sale of property, plant and equipment |
|
|
15 |
|
|
|
|
|
4 |
|
|
|
||
|
Free cash flow (non-GAAP measure) |
|
$ |
1,674 |
|
|
|
|
$ |
1,260 |
|
|
|
||
| Business Segment Information |
|
Three months ended |
||||||||||||
|
|
|
June 29, |
|
% of |
|
July 1, |
|
% of |
||||||
|
(Dollars in millions) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenues |
|
|
|
|
|
|
|
|
||||||
|
Life Sciences Solutions |
|
$ |
2,355 |
|
|
22.3 |
% |
|
$ |
2,463 |
|
|
23.0 |
% |
|
Analytical Instruments |
|
|
1,782 |
|
|
16.9 |
% |
|
|
1,749 |
|
|
16.4 |
% |
|
Specialty Diagnostics |
|
|
1,117 |
|
|
10.6 |
% |
|
|
1,109 |
|
|
10.4 |
% |
|
Laboratory Products and Biopharma Services |
|
|
5,758 |
|
|
54.6 |
% |
|
|
5,831 |
|
|
54.6 |
% |
|
Eliminations |
|
|
(470 |
) |
|
-4.5 |
% |
|
|
(465 |
) |
|
-4.4 |
% |
|
Consolidated revenues |
|
$ |
10,541 |
|
|
100.0 |
% |
|
$ |
10,687 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Segment income and segment income margin |
|
|
|
|
|
|
|
|
||||||
|
Life Sciences Solutions |
|
$ |
865 |
|
|
36.7 |
% |
|
$ |
817 |
|
|
33.2 |
% |
|
Analytical Instruments |
|
|
439 |
|
|
24.6 |
% |
|
|
432 |
|
|
24.7 |
% |
|
Specialty Diagnostics |
|
|
299 |
|
|
26.7 |
% |
|
|
297 |
|
|
26.7 |
% |
|
Laboratory Products and Biopharma Services |
|
|
745 |
|
|
12.9 |
% |
|
|
824 |
|
|
14.1 |
% |
|
Subtotal reportable segments |
|
|
2,347 |
|
|
22.3 |
% |
|
|
2,370 |
|
|
22.2 |
% |
|
Cost of revenues adjustments (a) |
|
|
(1 |
) |
|
0.0 |
% |
|
|
(18 |
) |
|
-0.2 |
% |
|
Selling, general and administrative expenses adjustments (b) |
|
|
64 |
|
|
0.6 |
% |
|
|
(6 |
) |
|
-0.1 |
% |
|
Restructuring and other costs (c) |
|
|
(77 |
) |
|
-0.7 |
% |
|
|
(183 |
) |
|
-1.7 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
(513 |
) |
|
-4.9 |
% |
|
|
(585 |
) |
|
-5.4 |
% |
|
Consolidated GAAP operating income |
|
$ |
1,820 |
|
|
17.3 |
% |
|
$ |
1,578 |
|
|
14.8 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 exclude $11 of charges for the sale of inventory revalued at the date of acquisition and $5 of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. |
||||||||||||||
|
(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration. |
||||||||||||||
|
(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 of contract termination costs associated with facility closures. |
||||||||||||||
|
(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments. |
||||||||||||||
|
(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements. |
||||||||||||||
|
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. |
||||||||||||||
|
Note: |
||||||||||||||
|
Consolidated depreciation expense is $276 and $270 in 2024 and 2023, respectively. |
||||||||||||||
| Organic and Core organic revenue growth |
|
Three months ended |
|
|
|
|
June 29, 2024 |
|
|
Revenue growth |
|
-1 % |
|
|
Acquisitions |
|
0 % |
|
|
Currency translation |
|
-1 % |
|
|
Organic revenue growth (non-GAAP measure) |
|
-1 % |
|
|
COVID-19 testing revenue |
|
-1 % |
|
|
Core organic revenue growth (non-GAAP measure) |
|
0 % |
|
|
|
|
|
|
|
Note: |
|
||
|
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
|
||
|
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
|
||||||
|
|
|
Six months ended |
||||||||||||
|
|
|
June 29, |
|
% of |
|
July 1, |
|
% of |
||||||
|
(Dollars in millions except per share amounts) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
|
Revenues |
|
$ |
20,886 |
|
|
|
|
$ |
21,397 |
|
|
|
||
|
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
|
Cost of revenues (a) |
|
|
12,146 |
|
|
58.2 |
% |
|
|
12,760 |
|
|
59.6 |
% |
|
Selling, general and administrative expenses (b) |
|
|
3,417 |
|
|
16.4 |
% |
|
|
3,319 |
|
|
15.5 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
1,065 |
|
|
5.1 |
% |
|
|
1,191 |
|
|
5.5 |
% |
|
Research and development expenses |
|
|
670 |
|
|
3.2 |
% |
|
|
691 |
|
|
3.2 |
% |
|
Restructuring and other costs (c) |
|
|
106 |
|
|
0.5 |
% |
|
|
295 |
|
|
1.4 |
% |
|
Total costs and operating expenses |
|
|
17,404 |
|
|
83.3 |
% |
|
|
18,256 |
|
|
85.3 |
% |
|
Operating income |
|
|
3,483 |
|
|
16.7 |
% |
|
|
3,141 |
|
|
14.7 |
% |
|
Interest income |
|
|
574 |
|
|
|
|
|
324 |
|
|
|
||
|
Interest expense |
|
|
(717 |
) |
|
|
|
|
(626 |
) |
|
|
||
|
Other income/(expense) (d) |
|
|
14 |
|
|
|
|
|
(46 |
) |
|
|
||
|
Income before income taxes |
|
|
3,354 |
|
|
|
|
|
2,793 |
|
|
|
||
|
Provision for income taxes (e) |
|
|
(408 |
) |
|
|
|
|
(98 |
) |
|
|
||
|
Equity in earnings/(losses) of unconsolidated entities |
|
|
(61 |
) |
|
|
|
|
(41 |
) |
|
|
||
|
Net income |
|
|
2,885 |
|
|
|
|
|
2,654 |
|
|
|
||
|
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
9 |
|
|
|
|
|
4 |
|
|
|
||
|
Net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,875 |
|
|
13.8 |
% |
|
$ |
2,650 |
|
|
12.4 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
|
||||||
|
Basic |
|
$ |
7.53 |
|
|
|
|
$ |
6.86 |
|
|
|
||
|
Diluted |
|
$ |
7.50 |
|
|
|
|
$ |
6.83 |
|
|
|
||
|
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
|
Basic |
|
|
382 |
|
|
|
|
|
386 |
|
|
|
||
|
Diluted |
|
|
383 |
|
|
|
|
|
388 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
|
GAAP operating income |
|
$ |
3,483 |
|
|
16.7 |
% |
|
$ |
3,141 |
|
|
14.7 |
% |
|
Cost of revenues adjustments (a) |
|
|
17 |
|
|
0.1 |
% |
|
|
59 |
|
|
0.3 |
% |
|
Selling, general and administrative expenses adjustments (b) |
|
|
(45 |
) |
|
-0.2 |
% |
|
|
14 |
|
|
0.1 |
% |
|
Restructuring and other costs (c) |
|
|
106 |
|
|
0.5 |
% |
|
|
295 |
|
|
1.4 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
1,065 |
|
|
5.1 |
% |
|
|
1,191 |
|
|
5.5 |
% |
|
Adjusted operating income (non-GAAP measure) |
|
$ |
4,625 |
|
|
22.1 |
% |
|
$ |
4,700 |
|
|
22.0 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
|
GAAP net income attributable to Thermo Fisher Scientific Inc. |
|
$ |
2,875 |
|
|
|
|
$ |
2,650 |
|
|
|
||
|
Cost of revenues adjustments (a) |
|
|
17 |
|
|
|
|
|
59 |
|
|
|
||
|
Selling, general and administrative expenses adjustments (b) |
|
|
(45 |
) |
|
|
|
|
14 |
|
|
|
||
|
Restructuring and other costs (c) |
|
|
106 |
|
|
|
|
|
295 |
|
|
|
||
|
Amortization of acquisition-related intangible assets |
|
|
1,065 |
|
|
|
|
|
1,191 |
|
|
|
||
|
Other income/expense adjustments (d) |
|
|
(11 |
) |
|
|
|
|
45 |
|
|
|
||
|
Provision for income taxes adjustments (e) |
|
|
(51 |
) |
|
|
|
|
(342 |
) |
|
|
||
|
Equity in earnings/losses of unconsolidated entities |
|
|
61 |
|
|
|
|
|
41 |
|
|
|
||
|
Noncontrolling interests adjustments (f) |
|
|
(1 |
) |
|
|
|
|
— |
|
|
|
||
|
Adjusted net income (non-GAAP measure) |
|
$ |
4,016 |
|
|
|
|
$ |
3,953 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
|
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
|
$ |
7.50 |
|
|
|
|
$ |
6.83 |
|
|
|
||
|
Cost of revenues adjustments (a) |
|
|
0.04 |
|
|
|
|
|
0.15 |
|
|
|
||
|
Selling, general and administrative expenses adjustments (b) |
|
|
(0.12 |
) |
|
|
|
|
0.03 |
|
|
|
||
|
Restructuring and other costs (c) |
|
|
0.28 |
|
|
|
|
|
0.76 |
|
|
|
||
|
Amortization of acquisition-related intangible assets |
|
|
2.78 |
|
|
|
|
|
3.07 |
|
|
|
||
|
Other income/expense adjustments (d) |
|
|
(0.03 |
) |
|
|
|
|
0.11 |
|
|
|
||
|
Provision for income taxes adjustments (e) |
|
|
(0.13 |
) |
|
|
|
|
(0.88 |
) |
|
|
||
|
Equity in earnings/losses of unconsolidated entities |
|
|
0.16 |
|
|
|
|
|
0.11 |
|
|
|
||
|
Noncontrolling interests adjustments (f) |
|
|
0.00 |
|
|
|
|
|
0.00 |
|
|
|
||
|
Adjusted EPS (non-GAAP measure) |
|
$ |
10.47 |
|
|
|
|
$ |
10.18 |
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||
|
Reconciliation of adjusted free cash flow |
|
|
|
|
|
|
|
|
||||||
|
GAAP net cash provided by operating activities |
|
$ |
3,211 |
|
|
|
|
$ |
2,269 |
|
|
|
||
|
Purchases of property, plant and equipment |
|
|
(648 |
) |
|
|
|
|
(742 |
) |
|
|
||
|
Proceeds from sale of property, plant and equipment |
|
|
20 |
|
|
|
|
|
10 |
|
|
|
||
|
Free cash flow (non-GAAP measure) |
|
$ |
2,583 |
|
|
|
|
$ |
1,537 |
|
|
|
||
|
Business Segment Information |
|
Six months ended |
||||||||||||
|
|
|
June 29, |
|
% of |
|
July 1, |
|
% of |
||||||
|
(Dollars in millions) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Revenues |
|
|
|
|
|
|
|
|
||||||
|
Life Sciences Solutions |
|
$ |
4,640 |
|
|
22.2 |
% |
|
$ |
5,075 |
|
|
23.7 |
% |
|
Analytical Instruments |
|
|
3,469 |
|
|
16.6 |
% |
|
|
3,472 |
|
|
16.2 |
% |
|
Specialty Diagnostics |
|
|
2,227 |
|
|
10.7 |
% |
|
|
2,217 |
|
|
10.4 |
% |
|
Laboratory Products and Biopharma Services |
|
|
11,480 |
|
|
55.0 |
% |
|
|
11,594 |
|
|
54.2 |
% |
|
Eliminations |
|
|
(930 |
) |
|
-4.5 |
% |
|
|
(961 |
) |
|
-4.5 |
% |
|
Consolidated revenues |
|
$ |
20,886 |
|
|
100.0 |
% |
|
$ |
21,397 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
Segment income and segment income margin |
|
|
|
|
|
|
|
|
||||||
|
Life Sciences Solutions |
|
$ |
1,705 |
|
|
36.7 |
% |
|
$ |
1,653 |
|
|
32.6 |
% |
|
Analytical Instruments |
|
|
838 |
|
|
24.2 |
% |
|
|
853 |
|
|
24.6 |
% |
|
Specialty Diagnostics |
|
|
593 |
|
|
26.6 |
% |
|
|
577 |
|
|
26.0 |
% |
|
Laboratory Products and Biopharma Services |
|
|
1,489 |
|
|
13.0 |
% |
|
|
1,617 |
|
|
14.0 |
% |
|
Subtotal reportable segments |
|
|
4,625 |
|
|
22.1 |
% |
|
|
4,700 |
|
|
22.0 |
% |
|
Cost of revenues adjustments (a) |
|
|
(17 |
) |
|
-0.1 |
% |
|
|
(59 |
) |
|
-0.3 |
% |
|
Selling, general and administrative expenses adjustments (b) |
|
|
45 |
|
|
0.2 |
% |
|
|
(14 |
) |
|
-0.1 |
% |
|
Restructuring and other costs (c) |
|
|
(106 |
) |
|
-0.5 |
% |
|
|
(295 |
) |
|
-1.4 |
% |
|
Amortization of acquisition-related intangible assets |
|
|
(1,065 |
) |
|
-5.1 |
% |
|
|
(1,191 |
) |
|
-5.5 |
% |
|
Consolidated GAAP operating income |
|
$ |
3,483 |
|
|
16.7 |
% |
|
$ |
3,141 |
|
|
14.7 |
% |
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines and accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Adjusted results in 2023 exclude $21 of charges for the sale of inventory revalued at the date of acquisition. |
||||||||||||||
|
(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration. |
||||||||||||||
|
(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 of contract termination costs associated with facility closures. |
||||||||||||||
|
(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments. |
||||||||||||||
|
(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements. |
||||||||||||||
|
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
||||||
|
Notes: |
||||||||||||||
|
Consolidated depreciation expense is $562 and $523 in 2024 and 2023, respectively. |
||||||||||||||
|
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
||||||||||||||
| Condensed Consolidated Balance Sheets (unaudited) |
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
June 29, |
|
December 31, |
||
|
(In millions) |
|
2024 |
|
2023 |
||
|
|
|
|
|
|
||
|
Assets |
|
|
|
|
||
|
Current assets: |
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
7,073 |
|
$ |
8,077 |
|
Short-term investments |
|
|
1,750 |
|
|
3 |
|
Accounts receivable, net |
|
|
7,943 |
|
|
8,221 |
|
Inventories |
|
|
5,198 |
|
|
5,088 |
|
Other current assets |
|
|
3,512 |
|
|
3,200 |
|
Total current assets |
|
|
25,476 |
|
|
24,589 |
|
Property, plant and equipment, net |
|
|
9,282 |
|
|
9,448 |
|
Acquisition-related intangible assets, net |
|
|
15,519 |
|
|
16,670 |
|
Other assets |
|
|
4,377 |
|
|
3,999 |
|
Goodwill |
|
|
43,843 |
|
|
44,020 |
|
Total assets |
|
$ |
98,496 |
|
$ |
98,726 |
|
|
|
|
|
|
||
|
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
|
||
|
Current liabilities: |
|
|
|
|
||
|
Short-term obligations and current maturities of long-term obligations |
|
$ |
5,121 |
|
$ |
3,609 |
|
Other current liabilities |
|
|
9,651 |
|
|
10,403 |
|
Total current liabilities |
|
|
14,772 |
|
|
14,012 |
|
Other long-term liabilities |
|
|
5,907 |
|
|
6,564 |
|
Long-term obligations |
|
|
30,284 |
|
|
31,308 |
|
Redeemable noncontrolling interest |
|
|
115 |
|
|
118 |
|
Total equity |
|
|
47,419 |
|
|
46,724 |
|
Total liabilities, redeemable noncontrolling interest and equity |
|
$ |
98,496 |
|
$ |
98,726 |
|
Condensed Consolidated Statements of Cash Flows (unaudited) |
|
|
|
|
||||
|
|
|
|
|
|
||||
|
|
|
Six months ended |
||||||
|
|
|
June 29, |
|
July 1, |
||||
|
(In millions) |
|
2024 |
|
2023 |
||||
|
|
|
|
|
|
||||
|
Operating activities |
|
|
|
|
||||
|
Net income |
|
$ |
2,885 |
|
|
$ |
2,654 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
|
Depreciation and amortization |
|
|
1,626 |
|
|
|
1,714 |
|
|
Change in deferred income taxes |
|
|
(607 |
) |
|
|
(328 |
) |
|
Other non-cash expenses, net |
|
|
311 |
|
|
|
480 |
|
|
Changes in assets and liabilities, excluding the effects of acquisitions |
|
|
(1,003 |
) |
|
|
(2,251 |
) |
|
Net cash provided by operating activities |
|
|
3,211 |
|
|
|
2,269 |
|
|
|
|
|
|
|
||||
|
Investing activities |
|
|
|
|
||||
|
Purchases of property, plant and equipment |
|
|
(648 |
) |
|
|
(742 |
) |
|
Proceeds from sale of property, plant and equipment |
|
|
20 |
|
|
|
10 |
|
|
Proceeds from cross-currency interest rate swap interest settlements |
|
|
111 |
|
|
|
35 |
|
|
Acquisitions, net of cash acquired |
|
|
— |
|
|
|
(2,751 |
) |
|
Purchases of investments |
|
|
(1,778 |
) |
|
|
(188 |
) |
|
Other investing activities, net |
|
|
12 |
|
|
|
51 |
|
|
Net cash used in investing activities |
|
|
(2,283 |
) |
|
|
(3,585 |
) |
|
|
|
|
|
|
||||
|
Financing activities |
|
|
|
|
||||
|
Net proceeds from issuance of debt |
|
|
1,204 |
|
|
|
— |
|
|
Repayment of debt |
|
|
— |
|
|
|
(1,000 |
) |
|
Net proceeds from issuance of commercial paper |
|
|
— |
|
|
|
1,620 |
|
|
Repayment of commercial paper |
|
|
— |
|
|
|
(1,441 |
) |
|
Purchases of company common stock |
|
|
(3,000 |
) |
|
|
(3,000 |
) |
|
Dividends paid |
|
|
(284 |
) |
|
|
(252 |
) |
|
Other financing activities, net |
|
|
145 |
|
|
|
24 |
|
|
Net cash used in financing activities |
|
|
(1,936 |
) |
|
|
(4,049 |
) |
|
|
|
|
|
|
||||
|
Exchange rate effect on cash |
|
|
7 |
|
|
|
(19 |
) |
|
Decrease in cash, cash equivalents and restricted cash |
|
|
(1,000 |
) |
|
|
(5,384 |
) |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
8,097 |
|
|
|
8,537 |
|
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
7,097 |
|
|
$ |
3,153 |
|
|
|
|
|
|
|
||||
|
Free cash flow (non-GAAP measure) |
|
$ |
2,583 |
|
|
$ |
1,537 |
|
|
|
||||||||
© 2024 Biopharma Boardroom. All Rights Reserved.
